Period:
Draw Mode:
| Volume | 5,625 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | GILD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.17 | 0.22% | 77.48 | 08:00:12 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 77.31 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 151 | 5,625 | - | 57.165 - 89.74 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:02:26 | 1 | $ 77.31 | USD |
Gilead Sciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 96.63B | 1.25B | 1.26B | $ 27.28B | $ 4.70B | 3.65 | 21.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ 2.92 | 3.88% | 03/14/23 | 315.52k | 0.70% |
Gilead Sciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GILD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 78.565 | 81.27 | 76.525 | 78.72 | 8,263,888 | -1.08 | -1.38% |
| 1 Month | 84.73 | 85.49 | 76.525 | 80.18 | 6,078,600 | -7.25 | -8.56% |
| 3 Months | 85.25 | 88.29 | 76.525 | 83.25 | 6,285,055 | -7.77 | -9.11% |
| 6 Months | 65.41 | 89.74 | 61.445 | 79.78 | 7,390,747 | 12.07 | 18.45% |
| 1 Year | 59.34 | 89.74 | 57.165 | 70.94 | 7,463,026 | 18.14 | 30.57% |
| 3 Years | 79.50 | 89.74 | 56.56 | 69.34 | 8,819,159 | -2.02 | -2.54% |
| 5 Years | 77.38 | 89.74 | 56.56 | 69.19 | 8,434,991 | 0.10 | 0.13% |
Gilead Sciences Description
| Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. |